Cardiac complications in cancer treatment - A review

Xianchi Li1, Min Liu1, Rongrong Sun1

  • 1Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province, China; The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu Province, China; Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu Province, China; Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu Province, China.

Insights

Cancer therapies can cause heart problems, leading to heart failure even after cancer survival. New research focuses on monitoring and managing this cardiotoxicity for better patient outcomes.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Effective cancer treatments, particularly targeted therapies, are increasingly linked to cardiac dysfunction.
  • Patients may survive cancer only to develop fatal heart failure, highlighting a critical survivorship issue.

Purpose of the Study:

  • To review current understanding of cardiac complications arising from cancer treatments.
  • To discuss recent advancements in monitoring and managing treatment-induced cardiotoxicity.

Main Methods:

  • This review synthesizes findings from recent research and clinical studies.
  • It examines technological advancements in the detection and management of cardiac dysfunction.

Main Results:

  • Anticancer therapies, including novel targeted agents, pose significant risks of cardiotoxicity.
  • Early detection and monitoring are crucial for mitigating long-term cardiac damage.

Conclusions:

  • Managing cardiotoxicity is essential for improving long-term survival and quality of life in cancer patients.
  • Continued research into novel monitoring and therapeutic strategies is vital.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
602
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
493
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
496
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566